ADS-J1 inhibits human immunodeficiency virus type 1 entry by interacting with the gp41 pocket region and blocking fusion-active gp41 core formation.
We previously identified a small-molecule anti-human immunodeficiency virus type 1 (anti-HIV-1) compound, ADS-J1, using a computer-aided molecular docking technique for primary screening and a sandwich enzyme-linked immunosorbent assay (ELISA) as a secondary screening method. In the present study, we demonstrated that ADS-J1 is an HIV-1 entry inhibitor, as determined by a time-of-addition assay and an HIV-1-mediated cell fusion assay. Further mechanism studies confirmed that ADS-J1 does not block gp120-CD4 binding and exhibits a marginal interaction with the HIV-1 coreceptor CXCR4. However, ADS-J1 inhibited the fusion-active gp41 core formation mimicked by peptides derived from the viral gp41 N-terminal heptad repeat (NHR) and C-terminal heptad repeat (CHR), as determined by ELISA, native polyacrylamide gel electrophoresis, and circular dichroism analysis. Moreover, using a surface plasmon resonance assay, we found that ADS-J1 could bind directly to IQN17, a trimeric peptide containing the gp41 pocket region, resulting in the conformational change of IQN17 and the blockage of its interaction with a short D peptide, PIE7. The positively charged residue (K574) located in the gp41 pocket region is critical for the binding of ADS-J1 to NHR. These results suggest that ADS-J1 may bind to the viral gp41 NHR region through its hydrophobic and ionic interactions with the hydrophobic and positively charged resides located in the pocket region, subsequently blocking the association between the gp41 NHR and CHR regions to form the fusion-active gp41 core, thereby inhibiting HIV-1-mediated membrane fusion and virus entry.
Wang
Hongtao
H
School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
Qi
Zhi
Z
Guo
Angi
A
Mao
Qinchao
Q
Lu
Hong
H
An
Xiuli
X
Xia
Chenglai
C
Li
Xiaojuan
X
Debnath
Asim K
AK
Wu
Shuguang
S
Liu
Shuwen
S
Jiang
Shibo
S
D019380:Anti-HIV Agents / Q000494:pharmacology*; D018952:Antigens, CD34 / Q000737:chemistry / Q000378:metabolism; D015704:CD4 Antigens / Q000378:metabolism; D045744:Cell Line, Tumor; D002942:Circular Dichroism; D004797:Enzyme-Linked Immunosorbent Assay; D015699:HIV Envelope Protein gp120 / Q000378:metabolism*; D015700:HIV Envelope Protein gp41 / Q000737:chemistry / Q000378:metabolism*; D015497:HIV-1 / Q000187:drug effects* / Q000378:metabolism*; D006801:Humans; D009282:Naphthalenesulfonates / Q000494:pharmacology*; D011485:Protein Binding / Q000187:drug effects; D011487:Protein Conformation / Q000187:drug effects; D019718:Receptors, CXCR4 / Q000378:metabolism; D014227:Triazines / Q000494:pharmacology*; D014779:Virus Replication / Q000187:drug effects
D019380:Anti-HIV Agents; D018952:Antigens, CD34; D015704:CD4 Antigens; D015699:HIV Envelope Protein gp120; D015700:HIV Envelope Protein gp41; D009282:Naphthalenesulfonates; D019718:Receptors, CXCR4; D014227:Triazines; C407145:ADS J1